Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595008 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
A Phase 2 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02595008 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 24 participants.
The verdict
NCT02595008, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
Interventions
- DRUG DSXS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-08-28 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595008
The ClinicalTrials.gov registry entry for NCT02595008 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DSXS is the first listed.
NCT02595008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595008 about?
NCT02595008 is a clinical study titled "Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis". this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
What is the current status of trial NCT02595008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-08-28. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT02595008?
The interventions under investigation include: DSXS (DRUG).
Who is sponsoring clinical trial NCT02595008?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.